Phase II clinical trial: Safety and efficacy study of tocilizumab (Toci) in combination with ipilimumab (Ipi) 3mg/kg plus nivolumab (Nivo) 1mg/kg in patients (pts) with metastatic melanoma (MM) Article

Full Text via DOI: 10.1016/j.annonc.2022.07.948 Web of Science: 000866211601093

Cited authors

  • Abdel-Wahab N, Montazari EJ, Spillson C, Amaria R, Glitza IC, Patel S, Awiwi M, Hassan A, Tahon N, Elsayes KM, Altan M, Wong M, Mcquade J, Tawbi HA, Davies M, Yee C, Sharma P, Allison J, Johnson D, Diab A

Publication date

  • 2022

Published in

International Standard Serial Number (ISSN)

  • 0923-7534

Number of pages

  • 1

Start page

  • S923

End page

  • S923


  • 33


  • 7